Related Experiment Video
Updated: Mar 14, 2026
Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022
Hematopoietic expression of cIAP2 drives inflammation and heart failure after myocardial infarction
David Smyth1, Liyong Zhang1, Mohammad Al-Khalaf1
1University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Insights
Cellular inhibitor of apoptosis 2 (cIAP2) worsens heart attack inflammation and injury. Inhibiting cIAP2 in immune cells reduces cardiac damage, offering a new therapeutic strategy for myocardial infarction (MI).
Area of Science:
- Cardiovascular Research
- Immunology
- Cell Death Regulation
Background:
- Ischemic heart disease, primarily myocardial infarction (MI), is a leading cause of death.
- Current therapies for post-MI inflammation have limited effectiveness.
- Cellular inhibitor of apoptosis 2 (cIAP2) regulates cell death and may impact cardiac injury.
Purpose of the Study:
- To investigate the role of cIAP2 in inflammation and cardiac injury following MI.
- To determine if cIAP2 inhibition can serve as a therapeutic strategy for MI.
Main Methods:
- Studied cIAP2 expression in a mouse model of MI.
- Utilized global cIAP2 deletion and bone marrow transfer models.
- Administered Smac mimetics to pharmacologically degrade cIAP proteins post-MI.
- Assessed cardiac inflammation, injury, and dysfunction.
Main Results:
- cIAP2 is upregulated after MI and exacerbates cardiac inflammation and injury.
- Loss of cIAP2 in hematopoietic cells reduced inflammatory injury and cardiac dysfunction.
- Reduced inflammation correlated with decreased splenic myeloid cells and increased TRAIL/TRAIL-R2 expression.
- Pharmacologic cIAP degradation post-MI reduced cardiac inflammation and injury.
Conclusions:
- cIAP2 is a key regulator of survival and inflammation in hematopoietic cells after MI.
- Inhibition of cIAP2 presents a potential immunotherapeutic strategy for treating myocardial infarction.
Abstract:
Ischemic heart disease, driven largely by myocardial infarction (MI), remains the leading cause of mortality and morbidity. Although early suppression of post-MI inflammation improves outcomes, current therapies have limited efficacy. Here we show that the cellular inhibitor of apoptosis 2 (cIAP2), a regulator of cell death, is upregulated after MI and promotes acute inflammation and cardiac injury. Global deletion of cIAP2, or its loss through bone marrow transfer, reduced inflammatory injury and cardiac dysfunction after MI, indicating that the cardioprotective effect of cIAP2 deficiency is primarily mediated by the hematopoietic compartment. Reduced cardiac inflammation was associated with decreased splenic myeloid cell numbers due to increased cell death and elevated expression of the death-inducing factors TRAIL and TRAIL-R2/DR5. Pharmacologic degradation of cIAP proteins after MI using Smac mimetics similarly reduced cardiac inflammation and protected against injury. Together, these findings identify cIAP2 as a key hematopoietic cell-expressed regulator of survival and inflammation and support its inhibition as a potential immunotherapeutic strategy for MI.
Related Concept Videos
01:21Myocarditis I: Introduction
01:01Regulation of Hematopoietic Stem Cells